Evaluation of synthetic peptides for human immunodeficiency virus antibody detection;Evaluación de péptidos sintéticos para la detección de anticuerpos contra el virus de inmunodeficiencia humana

Revista Argentina de Microbiologia

Volumn 35, Issue 3, 2003, Pages 149-155

  Lottersberger, J ^a   Salvetti, J L ^a   Tonarelli, G ^a  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

Diagnosis; ELISA; HIV; Synthetic peptides

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; SYNTHETIC PEPTIDE;

ANTIBODY DETECTION; ARGENTINA; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; SERUM; WESTERN BLOTTING;

AIDS SERODIAGNOSIS; AMINO ACID SEQUENCE; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY;

EID: 0142073237     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aleanzi M, Perotti N, Montaner A, Lottersberger J, Tonarelli G, Marcipar A (1996) Epitope contiguous chains and antibody recognition in HIV-1 synthetic peptide antigens. J. Mol. Recognit. 9: 631-638.
2. Andreu D, Rivas L (1997) Péptidos sintéticos en el estudio de la respuesta inmune en la infección del SIDA (VIH-1). En: Consejo Superior de Investigaciones Científicas (Ed), Péptidos en Biología y Biomedicina, RYCAR SA, Madrid, España, p. 433-462.
3. Atherton E, Sheppard R (1989) Solid phase peptide synthesis. En: Richwood D, Hames DB (Ed), Practical Approach Series, IRL Press, New York, p. 3-203.
4. Ball HL, Chan AW, Gibbons WA, Coates AR, Mascagni P (1997). The structural and aggregation properties of the synthetic C-terminal half (104-mer) polypeptide fron HIV p24 gag resemble those of full-length protein. J. Pept. Sci. 3:168-180.
5. Berry NJ, Salker R, Contreras M, Barbara JAJ, Tedder RS (1991). A comparison of four immunoassays for the simoultaneus detection of HIV-1 and HIV-2 specific antibody. J. Virol. Meth. 34: 91-100.
6. Blomberg J, Vincic E, Jönsson C, Medstrand P, Pipkorn R (1990). Identification of regions of HIV-1 p24 reactive with sera which give indeterminate results in electrophoresic immunoblots with the help of long synthetic peptides. AIDS Res. Hum. Retroviruses 6: 1363-1372.
7. Bukawa H, Fukushima J, Hamajima K, Kimura M, Tsuji T, Xin KQ, Okuda K (1995) Antibody responses raised against a conformational V3 loop peptide of HIV-1. Microbiol. Immunol. 39: 607-614.
8. Carr J, Avila M, Gómez Carrillo M, Salomón H, Hierholzer J, Veerachai W, et al (2001) Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS 15: F41-F47.
9. Chargelegue D, Stanley CM, O'Toole CM, Colvin BT, Steward MW (1995) The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin. Exp. Immunol. 99: 175-181.
10. Dyson HJ, Wright PE (1995) Antigenic peptides. FASEB J. 9: 37-42.
11. Farzadegan H, Chmiel J, Odaka N, Ward L, Poggense L, Saah A, Phair J (1992) Association of antibody to human immunodeficiency virus type 1 core protein (p24), CD4 lymphocyte number, and AIDS-free time. J. Infect. Dis. 166: 1217-1222.
12. Fields G, Noble R (1990) Solid phase peptide synthesis utilizing 9-fluorenilmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35: 161-214.
13. Flint SJ, Enquist LW, Krug RM, Racaniello VR, Skalka AM (2000) Human Immunodeficiency Virus. En: American Society of Microbiology (Ed), Principles of Virology. Molecular biology, Pathogenesis, and Control, ASM Press, Washington, p. 630-661.
14. Galai N, Muñoz A, Chen K, Carey V, Chmiel J, Zhou S (1993) Tracking of markers and onset of disease among HIV-1 seroconverters. Stat. Med. 12: 2133-2145.
15. Gómez Carrillo M, Avila M, Hierholzer J, Pando M, Martinez P, McCutchan F, Carr J (2002) Mother-to-child HIV type 1 transmission in Argentina: BF recombinants have predominated in infected children since the mid-1980s. AIDS Res. Hum. Retroviruses 18: 477-483.
16. Gómez Carrillo M, Mora J, Russi J (1995) Diagnóstico serológico de la infección por VIH. En: Organización Panamericana de la Salud (Ed), Garantía de calidad en el diagnóstico serológico de la infección por el virus de la inmunodeficiencia humana. Publicación No42. OPS, Buenos Aires, p. 16-29.
17. Javaherian K, Langlois AJ, Mc Danal C, Ross KL, Eckler LI, Jellis CL, et al (1989) Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 86: 6768-6772.
18. Jonhnson J (1992) Detection of human immunodeficiency virus type 1 antibody by using commercially available whole-cell viral lysate, synthetic peptide, and recombinant protein enzyme immunoassay systems. J. Clin. Microbiol. 30: 216-218.
19. Kaiser E, Colescott RL, Bossinger CD, Cook PI (1970) Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34: 595-598.
20. Lallement JC, Vendrell JP, Corbeau P, Ducos J, Segondy M, Escande A, et al (1993) Comparative humoral response to HIV-1-p24 gag linear B-cell epitopes among individuals showing atipicals Western Immunoblotting reactions and implications for diagnosis. J. Clin. Microbiol. 31: 1903-1907.
21. Leinikki P, Lehtinen M, Hyöty H, Parkkonen P, Kantanen M, Hakulinen J (1993) Synthetic peptides as diagnostic tools in virology. Adv. Virus Res. 42: 146-186.
22. Lindhart B (1991) Serological investigations of human immunodeficiency virus infection. Dan. Med. Bull. 38: 22-36.
23. Lottersberger J, Saivetti JL, Tonarelli G (1998) Capacidad funcional de péptidos sintéticos que imitan secuencias antigénicas del loop V3 de la gp120 de HIV-1. FABICIB 2: 83-89.
24. Lottersberger J, Salvetti JL, Negri L, Perin JC, Montaner A, Tonarelli G (2000) Evaluación de la inmunoreactividad de péptidos sintéticos de las proteínas p22, NS4 y NS5 del Virus de Hepatitis C. Infect. Microbiol. Clin. 12: 74-81.
25. McRae B, Lange J, Ascher M, de Wolf, F, Sheppard HW, Goudsmit J, Allain JP (1991) Immune response to HIV p24 core protein during the early phases of inimmunodeficiency virus infection. AIDS Res. Hum. Retoviruses 7: 637-643.
26. Misselwitz R, Hausdorf G, Welfe K, Höhne W, Welfe H (1995) Conformation and stability of recombinant HIV-1 capsid protein p24 (rp24). Biochim. Biophys. Acta 1250: 9-18.
27. Niedrig M, Hinkula J, Weigelt W, Age-Stehr JL, Pauli G, Rosen J, Wahren B (1989) Epitope mapping of monoclonal antibodies against HIV type 1 structural proteins by using peptides. J. Virol. 63: 3525-3528.
28. Oldstone M, Tishon A, Lewicki H, Dyson H, Feher V, Assa-Munt N, Wright P (1991) Mapping the anatomy of the immunodominant domain of the HIV gp41 transmembrane protein: peptide conformationm analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy. J. Virol. 65: 1727-1734.
29. Pampuro S, Calarota S, Marquina S, Rabinovich R, Libonatti O (1996) Reactivity of Argentine seum samples against synthetic V3-based HIV-1 peptides. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12: 527-528.
30. Proffitt M (1993) Adquired immunodeficiency syndrome. Anal. Chem. 65: 369R-400R.
31. Richalet-Sécordel P, Zeder-Lutz G, Plaue S, Sommermeyer-Leroux G, Van Regenmortel MHV (1994) Cross-reactivity of monoclonal antibodies to a chimeric V3 peptide of HIV-1 with peptide analogues studied by biosensor technology and ELISA. J. Immunol. Meth. 176: 221-234.
32. Saito A, Morimoto M, Ohara T, Takamizawa A, Nakata A, Shinagawa H (1995) Overproduction, purification and diagnostic use of the recombinant HIV-1 gag proteins, the precursor protein p55 and the processed products p17, p24, and p15. Microbiol. Immunol. 39: 473-483.
33. Soutullo A, Verwimp V, Riveros M, Pauli R, Tonarelli G (2000) Design and validation of an ELISA for equine infectious anemia (E.I.A.) diagnosis using synthetic peptides. Vet. Mic. 79: 111-121.
34. Strathdee S, Frank J, McLaughlin J, Leblanc M, Major C, O'Shaughnessy M, Read S (1995) Quantitative measures of human immunodeficiency virus-specific antibodies predict progressin to AIDS. J. Infect. Dis. 172: 1375-1379.
35. Tijssen J (1987) Processing of data and reporting of results of enzyme immunoassays. En: Bourdon RH, Van Knippenberg PH (Ed), Practice and theory of enzyme immunoassay laboratory techniques in biochemistry and molecular biology. Elsevier, Amsterdam, The Netherlands, p. 385-421.
36. Tonarelli G, Lottersberger J, Salvetti J, Sacheri S, Silva-Lucca R, Beltramini L (2001) Secondary structure-improved bioaffinity correlation in elongated and modified synthetic epitope peptides from p24 HIV-1 core protein. LIPS 7: 217-224.
37. Van Regenmortel MHV (1993) Synthetic peptides versus natural antigens in immunoassays. Ann. Biol. Clin. 51: 39-41.
38. Wagner R, Modrow S, Boltz T, Fliessbach H, Niedrig M, Von Brunn A, Wolf H (1992) Immunological reactivity of a human immunodeficiency virus type-1 derived peptide presenting a consensus sequence of the gp120 major neutralizing region V3. Arch. Virol. 127: 139-152.
39. Warren R, Wong M, Melcher G, Blatt S, Cahn P, Pérez H, et al (1995) Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates. J. Clin. Microbiol. 33: 481-483.
40. WHO Scientific Group (1989) Synthetic antigens in diagnosis of human innunodeficiency virus (HIV) infection. In: World Health Organization (Ed), The use of synthetic antigens for diagnosis of infectious diseases, Technical Report Series 784. Geneva. Switzerland, p. 34-48.